UK Markets close in 47 mins

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
41.31-0.50 (-1.20%)
As of 10:28AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close41.81
Open41.33
BidN/A x N/A
AskN/A x N/A
Day's range41.21 - 41.46
52-week range37.88 - 53.86
Volume72,501
Avg. volume2,564,154
Market cap285.464B
Beta (5Y monthly)0.31
PE ratio (TTM)18.69
EPS (TTM)2.21
Earnings dateN/A
Forward dividend & yield1.24 (3.12%)
Ex-dividend date17 Mar 2022
1y target est58.30
  • Globe Newswire

    Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care

    The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide high-quality, time-critical results to doctors and patients.With laboratory diagnostics involved in more than two-thirds of healthcare decision making, innovative laboratory solutions that enable an accurate and timely diagnosis are crucial to successful treatment.About 17 million new cases of cancer are diagnosed worldwide each ye

  • Globe Newswire

    Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics

    The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment.Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.1 Many cancers can be cured if detected early and treated effectively.1The Roche Digital Pathology solution helps empower the digital transformation of pathology and enable bette

  • Zacks

    Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051

    The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.